ClinicalTrials.gg
RecruitingNCT06467903RetinaUpdated Jun 21, 2024

Evaluation Conducted to Capture Patients With Diabetic Retinopathy in General Practitioners, Using SW as Medical Device

An interventional study of SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) . in Diabetes Mellitus, sponsored by Bonmedix Holding a.s.. Recruiting at 1 site in Czechia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by Bonmedix Holding a.s. · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 120 studies in Diabetes Mellitus with a site in Czechia — 8 open to participants now, 12 under way, 3 of them phase 3. Diabetes Mellitus · Czechia.

Planned enrollment
30th of 108
1,000 · median 464
Started
2024
with 5 others
No phase
14 of 120
3 open now
Primary completion
2024-10
later than 0 of 11 live
Registered
113th of 120
by date

Among the 120 studies in Diabetes Mellitus with a site in Czechia, this one is the 30th largest by planned enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2024, is one of 14 with no phase, reaches primary completion later than 0 of the 11 other live ones, and was the 113th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

8 of the 120 studies in Diabetes Mellitus with a site in Czechia are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies in Diabetes Mellitus with a site in Czechia, or all of them as a file.
02

Study summary

A prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using AI medical device

Read the detailed description

A prospective, comparative multicenter evaluation conducted to capture patients with diabetic retinopathy in general practitioners, using the SWaMD medical device and the SWaMD comparator, when evaluating the patients retinal image

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged ≥ 40 years
  • Signed
  • Confirmed type 1 or 2 diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  • Ocular findings that do not allow retinal photography (significant nystagmus, corneal leukoma, dense cataract, hemophthalmus, etc.)
  • Patient has a condition or is in a situation that, in the opinion of the investigator, may bias the results of the study, may significantly interfere with the patient's participation in the investigation, or may result in unproducible photographs of a dilated ocular fundus
  • Patients with restrictions on personal freedom by administrative or legal order
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    one arm - 1000 patients, DR screening

    SW as medical devices(investigational device) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .

    Device: SW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .

Interventions

  • DeviceSW as medical devices(comperator) to evaluate the retinal image of the patient's eye (to identify if the patient has DR or if the patient is healthy) .

    second AI medical device to evaluate the retinal image of the patient's eye. two AI as MD will be evaluating the retinal image

06

What researchers measure

Primary outcomes

  1. Sensitivity and specificity

    The sensitivity and specificity will be calculated using the evaluation of independent masked expert (ophthalmologist) as gold standard.

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Jakub Sedivy
    Příbram, Or, Czechia
    Recruiting
    • Sedivy, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Oct 2024, 4 months after the start.

Of 160 industry-sponsored interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 4 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 21, 2024
StartActual
Jun 7, 2024
Primary completionEst.
Oct 28, 2024
CompletionEst.
Dec 15, 2024
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06467903
Lead sponsor
Bonmedix Holding a.s.
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Jun 7, 2024
Primary completion
Oct 28, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Jun 21, 2024

Study contacts

Pavlina Kasparova Walter, MBA
Contact
pavlinakasparova@gmail.com
776661512 ext. 00420
Jiří Tomšej, ING
Contact
tomsej@viderai.com
777108402 ext. 00420
Petr Šonka, MD
principal investigator · GP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion